Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

The Neuralert Stroke Monitor Pilot Trial

NCT06368193 · tracked via the Priya Life Science USA tracker
Sponsor
Neuralert Technologies LLC
Phase
Not applicable
Started
2024-12-12
Last updated
2026-01-20

Condition(s) studied

StrokeSurgery

Investigational drug(s) / intervention(s)

Neuralert Monitor

Neuralert Monitor: Device to identify upper extremity asymmetry in patients who are high risk for stroke.

Study summary

This trial aims to demonstrate that the Neuralert Monitoring System will detect strokes before they would be identified by current standard of care. Each patient will be monitored for up to five days, depending on device connectivity or battery duration. Each monitoring session will consist of wearing a Neuralert device on each arm. For this pilot trial, we are interested in learning about Wi-Fi connectivity, successful data transmission, integration into clinical workflow, usability and tolerability.

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
1. Male or female age ≥ 22 years 2. Admitted or planned admission to one of the participating hospitals and followed by the Cardiothoracic (CT) Surgery or Vascular Surgery services 3. Considered at high risk for stroke while in the hospital based on: Ø Interventions or procedures that are high-risk for stroke performed during the hospitalization, which may include: * Intracardiac surgical or endovascular procedures, including valve replacement * Ascending aorta or aortic arch surgical or endovascular repair * Open surgical or endovascular carotid revascularization Ø Other cardiac procedures along with a high-risk medical history: * Age ≥ 80 years · Prior stroke/TIA * Hypercoagulable state (i.e., prior clotting events attributed to active malignancy or a diagnosed thrombophilia) requiring lifelong anticoagulation * Severely reduced left ventricular cardiac ejection fraction (i.e., \<30%) or anterior left ventricular wall akinesis * Atrial fibrillation 4. Admitted with a stroke or TIA attributed to large artery occlusion or severe stenosis that has not been revascularized. Exclusion Criteria: (all must be no) 1. Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study 2. Baseline preoperative asymmetric upper extremity weakness as assessed by the Investigator, defined as a differential in the NIHSS upper extremity motor score between the two arms of \>0 3. Above the wrist amputation 4. Unwilling to provide informed consent or no legally authorized representative willing to provide consent if the patient is unable 5. Currently imprisoned

Primary outcome measure(s)

  • Time to Nursing Response — Up to 5 days post patient surgery
    The time from the nurse receiving an alert to the time they respond after assessing the patient.
  • Time to Generate Alert — Up to 5 days post patient surgery
    The time to successful generation of an alert to staff when asymmetry or low battery is detected.

Trial sites (1)

FacilityCityRegionStatus
Hospital of the University of Pennsylvania Philadelphia Pennsylvania Recruiting

More Neuralert Technologies LLC trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06368193 on ClinicalTrials.gov ↗ ← All trials in the USA